Cancer cell survival depends on collagen uptake into tumor-associated stroma
Kuo-Sheng Hsu(National Cancer Institute), Brad St. Croix(National Cancer Institute), Nancy J. Emenaker(National Institutes of Health), Enrique Zudaire(Centro de Investigación del Cáncer), Lino Tessarollo(National Institutes of Health), Francesco Tomassoni‐Ardori(Frederick National Laboratory for Cancer Research), Mary Beth Hilton(Frederick National Laboratory for Cancer Research), Emily Lutz(Frederick National Laboratory for Cancer Research), James M. Dunleavey(Frederick National Laboratory for Cancer Research), Yang Feng(University of Florida), Robert Koogle(Frederick National Laboratory for Cancer Research), Saurabh Saha(Phenomenome Discoveries (Canada)), Steven Seaman(Frederick National Laboratory for Cancer Research), Pradip Bajgain(Baylor College of Medicine), Dimiter S. Dimitrov(University of Pittsburgh), Xiaoyan Zhang(Shanghai Jiao Tong University), Liping Yang(Xinjiang Normal University), Karen Morris(Cancer Research UK Manchester Institute), Zhongyu Zhu(Frederick National Laboratory for Cancer Research), Joshua Rose(College of Alameda), Christopher Szot(Leidos (United States)), Frank Cuttitta(Frederick National Laboratory for Cancer Research)
Cited by 5
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
|Cancer Discovery|2017|418
Bcl11a is essential for normal lymphoid development
|Nature Immunology|2003|358